Bansi Desai, VP–India Healthcare & Pharma Research at JPMorgan said CDMO firms plan to expand capacity with capex in 2024 at about 30% of existing gross block and are moving into complex areas like advanced drug conjugates, oligonucleotides, and peptides.
